

Deborah M Siegal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9003231/publications.pdf>

Version: 2024-02-01

110
papers

8,554
citations

116194

36
h-index

51423

90
g-index

110
all docs

110
docs citations

110
times ranked

8810
citing authors

#	ARTICLE	IF	CITATIONS
1	Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. <i>New England Journal of Medicine</i> , 2015, 373, 2413-2424.	13.9	907
2	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	13.9	778
3	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	13.9	712
4	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	13.9	692
5	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	13.9	687
6	Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1128-1139.	1.2	414
7	Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists. <i>Circulation</i> , 2012, 126, 1630-1639.	1.6	406
8	American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. <i>Blood Advances</i> , 2021, 5, 872-888.	2.5	310
9	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3042-3067.	1.2	285
10	Clinical Impact of Community-Acquired Respiratory Viruses on Bronchiolitis Obliterans After Lung Transplant. <i>American Journal of Transplantation</i> , 2005, 5, 2031-2036.	2.6	249
11	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. <i>Chest</i> , 2017, 151, 127-138.	0.4	245
12	The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. <i>Blood</i> , 2016, 128, 138-140.	0.6	190
13	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2020, 76, 594-622.	1.2	187
14	Acute management of bleeding in patients on novel oral anticoagulants. <i>European Heart Journal</i> , 2013, 34, 489-498.	1.0	152
15	Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study. <i>Lancet, The</i> , 2019, 394, 1022-1029.	6.3	146
16	Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1369-1379.	2.0	143
17	Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 879-890.	1.8	139
18	How I treat target-specific oral anticoagulant-associated bleeding. <i>Blood</i> , 2014, 123, 1152-1158.	0.6	108

#	ARTICLE	IF	CITATIONS
19	A Trial of Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Lung Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 1462-1468.	2.6	89
20	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-critically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	3.8	89
21	Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. <i>Blood Advances</i> , 2017, 1, 772-778.	2.5	82
22	Reversal of novel oral anticoagulants in patients with major bleeding. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 391-398.	1.0	78
23	A Randomized, Double-Blind Trial of Pneumococcal Vaccination in Adult Allogeneic Stem Cell Transplant Donors and Recipients. <i>Clinical Infectious Diseases</i> , 2007, 45, 1576-1582.	2.9	74
24	Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1966-1972.	1.9	70
25	A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Prime-Boost Strategy for Pneumococcal Vaccination in Adult Liver Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2008, 47, 885-892.	2.9	67
26	Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 395-402.	1.0	66
27	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. <i>Blood Advances</i> , 2022, 6, 664-671.	2.5	53
28	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 117-124.	0.9	50
29	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. <i>Blood Advances</i> , 2017, 1, 1827-1838.	2.5	50
30	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. <i>Blood Advances</i> , 2021, 5, 3951-3959.	2.5	49
31	Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019, 175, 102-109.	0.8	49
32	Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019, 179, 81-86.	0.8	47
33	A Prospective Assessment of Valganciclovir for the Treatment of Cytomegalovirus Infection and Disease in Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2005, 192, 1154-1157.	1.9	46
34	Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia. <i>Annals of Internal Medicine</i> , 2017, 167, 170.	2.0	42
35	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. <i>Blood Advances</i> , 2022, 6, 4915-4923.	2.5	42
36	Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia. <i>Seminars in Hematology</i> , 2013, 50, S18-S21.	1.8	39

#	ARTICLE	IF	CITATIONS
37	Pharmacological reversal of the direct oral anticoagulants—A comprehensive review of the literature. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 251-265.	1.0	35
38	Reversal of target-specific oral anticoagulants. <i>Drug Discovery Today</i> , 2014, 19, 1465-1470.	3.2	32
39	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 231-239.	1.0	32
40	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. <i>Cardiovascular Research</i> , 2021, 117, 576-584.	1.8	31
41	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. <i>British Journal of Anaesthesia</i> , 2021, 126, 163-171.	1.5	29
42	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations. <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	1.8	28
43	Use of Kidney Function End Points in Kidney Transplant Trials: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1140-1157.	2.1	23
44	Blood loss from laboratory testing, anemia, and red blood cell transfusion in the intensive care unit: a retrospective study. <i>Transfusion</i> , 2020, 60, 256-261.	0.8	23
45	Iron deficiency following bariatric surgery: a retrospective cohort study. <i>Blood Advances</i> , 2020, 4, 3639-3647.	2.5	23
46	Brain vesicular acetylcholine transporter in human users of drugs of abuse. <i>Synapse</i> , 2004, 52, 223-232.	0.6	22
47	Acute Hepatic Necrosis and Ischemic Limb Necrosis. <i>New England Journal of Medicine</i> , 2012, 367, 879-881.	13.9	21
48	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. <i>Blood Advances</i> , 2022, 6, 4975-4982.	2.5	21
49	Anticoagulant-associated gastrointestinal bleeding: Framework for decisions about whether, when and how to resume anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2383-2393.	1.9	19
50	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2017, 160, 97-104.	0.8	18
51	Devices to Reduce the Volume of Blood Taken for Laboratory Testing in ICU Patients: A Systematic Review. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 1074-1079.	1.3	17
52	Specific antidotes for bleeding associated with direct oral anticoagulants. <i>BMJ: British Medical Journal</i> , 2017, 357, j2216.	2.4	15
53	Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2008-2015.	1.9	15
54	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	3.0	15

#	ARTICLE	IF	CITATIONS
55	Intravenous iron therapy for patients with preoperative iron deficiency or anaemia undergoing cardiac surgery reduces blood transfusions: a systematic review and meta-analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 31, 141-151.	0.5	14
56	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1097-1106.	1.8	14
57	Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding. <i>Cmaj</i> , 2021, 193, E304-E309.	0.9	13
58	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 627 2019, 45, 793-801.	1.5	12
59	Management of antithrombotic therapy after gastrointestinal bleeding: A mixed methods study of health care providers. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 153-160.	1.9	12
60	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 117-124.	0.9	12
61	No apparent association between mRNA COVID-19 vaccination and venous thromboembolism. <i>Blood Reviews</i> , 2022, 56, 100970.	2.8	12
62	Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1910-1919.	1.9	12
63	What we have learned about direct oral anticoagulant reversal. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 198-203.	0.9	11
64	Thinking Outside the Inbox: Use of Slack in Clinical Groups as a Collaborative Team Communication Platform. <i>AEM Education and Training</i> , 2021, 5, 121-129.	0.6	10
65	Oral Anticoagulant Use in Patients with Morbid Obesity: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2022, 122, 830-841.	1.8	10
66	Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate. <i>Thrombosis Research</i> , 2017, 157, 165-166.	0.8	9
67	Detection of right ventricular dysfunction in acute pulmonary embolism by computed tomography or echocardiography: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2504-2513.	1.9	9
68	Occult Amebic Liver Abscess as Cause of Extensive Inferior Vena Cava and Hepatic Vein Thrombosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1214-1217.	0.6	9
69	Small-Volume Tubes to Reduce Transfusion (STRATUS): A Pilot Study. <i>Blood</i> , 2018, 132, 825-825.	0.6	9
70	Complete heart block following intentional carbamate ingestion. <i>Canadian Journal of Cardiology</i> , 2009, 25, e288-e290.	0.8	8
71	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. <i>British Journal of Anaesthesia</i> , 2021, 126, 172-180.	1.5	8
72	Ethnoracial variations in venous thrombosis: Implications for management, and a call to action. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 30-40.	1.9	8

#	ARTICLE	IF	CITATIONS
73	Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIMaLine): A two-center open-label pilot randomized controlled trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12517.	1.0	8
74	Barriers and facilitators for optimizing oral anticoagulant management: Perspectives of patients, caregivers, and providers. <i>PLoS ONE</i> , 2021, 16, e0257798.	1.1	8
75	Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS): A Pragmatic Stepped Wedge Cluster Randomized Trial. <i>Blood</i> , 2019, 134, 3685-3685.	0.6	8
76	Type II Bidirectional Ventricular Tachycardia as a Mechanism of Termination of Sustained Ventricular Tachycardia. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 345-346.	0.8	7
77	What is the effect of rivaroxaban on routine coagulation tests?. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 334-336.	0.9	7
78	A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies. <i>Blood Advances</i> , 2020, 4, 6259-6273.	2.5	7
79	Plasma versus prothrombin complex concentrate for warfarin-associated major bleeding: a systematic review. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 448-453.	0.9	6
80	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. <i>Thrombosis Research</i> , 2018, 163, 19-21.	0.8	6
81	Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. <i>Future Cardiology</i> , 2019, 15, 395-404.	0.5	5
82	The real-world outcomes of treating Polycythemia Vera: Physician adherence to treatment guidelines. <i>Leukemia Research</i> , 2018, 70, 62-66.	0.4	4
83	The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-Analysis. <i>American Journal of Gastroenterology</i> , 2019, 114, S332-S333.	0.2	4
84	Prothrombin complex concentrates for DOAC-associated bleeding, global coagulation assays, and assessments of clinical hemostasis: How to gauge the impact?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 677-679.	1.0	4
85	Perceptions of patients and healthcare providers on patient education to improve oral anticoagulant management. <i>Journal of Evaluation in Clinical Practice</i> , 2022, 28, 1027-1036.	0.9	4
86	Illustrated State of the Art Capsules of the ISTH 2022 Congress. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12747.	1.0	4
87	Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds. <i>Circulation</i> , 2019, 139, 757-759.	1.6	3
88	Refractory urticaria and the importance of diagnosing Schnitzler's syndrome. <i>BMJ Case Reports</i> , 2019, 12, e228546.	0.2	3
89	Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 204-208.	0.9	3
90	Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk. <i>Heart</i> , 2020, 106, 845-851.	1.2	3

#	ARTICLE	IF	CITATIONS
91	Are the correct outcomes being measured in studies of oral anticoagulants? A systematic survey. <i>Thrombosis Research</i> , 2021, 201, 30-49.	0.8	3
92	Incidence of stroke in the first year after diagnosis of cancer—A protocol for systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0256825.	1.1	3
93	Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practice. <i>Thrombosis Research</i> , 2018, 167, 6-8.	0.8	1
94	Shared Decision-Making for Anticoagulation in Atrial Fibrillation: Do Physicians Really Listen?. <i>Canadian Journal of Cardiology</i> , 2020, 36, 459-461.	0.8	1
95	Narrowing in on the True Rate of Venous Thromboembolism in Hospitalized Patients With COVID-19 Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1958-1960.	1.1	1
96	Ciraparantag: the next anticoagulant airbag?. <i>Blood</i> , 2021, 137, 10-11.	0.6	1
97	Considerations for use of direct oral anticoagulants in arterial disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12502.	1.0	1
98	The Use of Transthoracic Echocardiograms in Hospitalized Adult Patients with Acute Pulmonary Embolism. <i>Blood</i> , 2020, 136, 43-43.	0.6	1
99	Perioperative Heparin Bridging in Patients Receiving Oral Anticoagulation: Meta-Analysis of Bleeding and Thromboembolic Rates. <i>Blood</i> , 2011, 118, 545-545.	0.6	1
100	Non-Specific Hemostatic Agents (PCC, aPCC, rVIIa) for Reversal of Direct Oral Anticoagulant Effect in Patients with Major Bleeding Complications: A Retrospective Review. <i>Blood</i> , 2015, 126, 1137-1137.	0.6	1
101	Efficacy and Safety of Weight-Adjusted Extended Duration Tinzaparin for Prevention of Post-Operative Venous Thromboembolism after Bariatric Surgery. <i>Blood</i> , 2015, 126, 1130-1130.	0.6	1
102	Characterizing Frailty in Myeloproliferative Neoplasms: Baseline Results from the Orchid Study. <i>Blood</i> , 2020, 136, 9-10.	0.6	1
103	Association of direct oral anticoagulant-proton pump inhibitor cotherapy with adverse outcomes: protocol for a population-based cohort study. <i>BMJ Open</i> , 2022, 12, e057991.	0.8	1
104	2. Abstract Title: Risk of venous and arterial thrombosis in patients receiving tranexamic acid: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2018, 170, 2.	0.8	0
105	Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding. <i>Thrombosis Research</i> , 2019, 180, 86.	0.8	0
106	Media portrayals of pulmonary embolism. <i>Thrombosis Research</i> , 2021, 206, 52-54.	0.8	0
107	Blood Loss Due to Laboratory Testing in Critical Care Patients: A Retrospective Cohort Study. <i>Blood</i> , 2018, 132, 4885-4885.	0.6	0
108	A Population Cohort Study to Evaluate the Risk of Ischemic Stroke Among Individuals with a New Diagnosis of Cancer Compared to Matched Cancer-Free Controls: Impact of Prior Stroke History. <i>Blood</i> , 2021, 138, 175-175.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Detection of Right Ventricular Dysfunction in Acute Pulmonary Embolism By CT Scan: A Systematic Review and Meta-Analysis. Blood, 2020, 136, 25-26.	0.6	0
110	Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study. Leukemia Research, 2022, 113, 106788.	0.4	0